Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Alerta

Resultados 61 resultados
LastUpdate Última actualización 15/03/2025 [07:49:00]
pdfxls
Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days
Resultados 1 a 25 de 61 nextPage  

USE OF PERIPHERAL BLOOD MACROPHAGES IN PREPARATION OF REAGENT AND/OR DRUG FOR DIAGNOSIS, PROGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE

NºPublicación:  WO2025050415A1 13/03/2025
Solicitante: 
HUNAN QANKOREY BIOTECHNOLOGY COMPANY LTD [CN]
\u6E56\u5357\u4E7E\u5EB7\u79D1\u6280\u6709\u9650\u516C\u53F8
WO_2025050415_PA

Resumen de: WO2025050415A1

Disclosed in the present invention is the use of peripheral blood macrophages in the preparation of a reagent and/or a drug for the diagnosis, prognosis and treatment of Alzheimer's disease (AD). The present invention will open new doors for a better understanding of the disease mechanisms of Alzheimer's disease and may guide development in new directions for early diagnosis, prognosis and treatment, so as to enable early prevention and treatment of Alzheimer's disease.

ANTIBODY BASED REAGENTS THAT SPECIFICALLY RECOGNIZE TOXIC OLIGOMERIC FORMS OF TAU

NºPublicación:  US2025084157A1 13/03/2025
Solicitante: 
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIV [US]
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
EP_4356927_A2

Resumen de: US2025084157A1

The invention relates to antibodies, antibody fragments and binding agents that specifically recognize oligomeric tau but do not bind to monomeric tau, fibrillar tau or non-disease associated forms of tau.

METHODS OF REDUCING NEURODEGENERATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES

NºPublicación:  AU2023347307A1 13/03/2025
Solicitante: 
EISAI R&D MANAGEMENT CO LTD
WASHINGTON UNIV
EISAI R&D MANAGEMENT CO., LTD,
WASHINGTON UNIVERSITY
AU_2023347307_A1

Resumen de: AU2023347307A1

The disclosure relates to lemborexant, a dual orexin receptor antagonist, and compositions and methods for use in treatment of Alzheimer's disease (AD), e.g., in a subject who has AD or who is at risk for developing AD.

DETECTION OF DEMENTIA BIOMARKERS USING APTAMER-MODIFIED GRAPHENE FIELD-EFFECT TRANSISTORS

NºPublicación:  WO2025054610A1 13/03/2025
Solicitante: 
THE REGENTS OF THE UNIV OF CALIFORNIA [US]
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
WO_2025054610_PA

Resumen de: WO2025054610A1

Dementia is a brain disease which results in irreversible and progressive loss of cognition and motor activity. Despite global efforts, there are no simple and reliable diagnosis or treatment options. Embodiments of the disclosed technology provide an aptamer-based graphene field-effect transistor (GFET) biosensor platform that has high sensitivity and precision across a range of epidemiologically significant Alzheimer's disease and Parkinson's disease variants, and enables at-home and point-of-care (POC) testing for neurodegenerative diseases. An example method of detecting for detecting a molecular biomarker for dementia of a subject includes receiving a biological sample comprising the molecular biomarker for dementia, contacting the biological sample with a biosensor device comprising a GFET-based detection chip, and detecting a presence of the molecular biomarker for dementia in the biological sample.

DIAGNOSTIC METHOD

NºPublicación:  EP4519687A1 12/03/2025
Solicitante: 
UNIV DEGLI STUDI MILANO [IT]
UNIVERSITA' DEGLI STUDI DI MILANO
WO_2023214324_A1

Resumen de: WO2023214324A1

The present invention relates to a method for diagnosing neurodegenerative diseases, wherein said method comprises measuring the JNK3 levels in a biological sample selected from plasma, CSF, and saliva. In an embodiment, said method also comprises measuring P-JNK3.

生物标志物联合检测及应用

NºPublicación:  CN119574889A 07/03/2025
Solicitante: 
中元汇吉生物技术股份有限公司
CN_119574889_PA

Resumen de: CN118731373A

The invention belongs to the field of biological medicine, and particularly relates to a combination for joint detection of Alzheimer's disease biomarkers and application. The invention provides an application of a biomarker group in detection of Alzheimer's disease, and is characterized in that the biomarker group comprises: a) at least two of APOE4, GDF-15, UCH-L1 and PF4; or b) at least one of APOE4, GDF-15, UCH-L1 and PF4, as well as a phosphorylated Tau protein and a total Tau protein. The invention also provides a kit for detecting the Alzheimer's disease. According to the invention, more effective detection and diagnosis of the Alzheimer's disease are facilitated, and a new path is provided for detection and prevention of AD.

Anti-Tau antibodies and methods of their use

NºPublicación:  AU2025201059A1 06/03/2025
Solicitante: 
GENENTECH INC
AC IMMUNE SA
Genentech, Inc,
AC Immune SA
AU_2025201059_A1

Resumen de: AU2025201059A1

The invention provides anti-Tau antibodies and methods of using the same.

PEPTIDES FOR THE DETECTION OF AMYLOID FIBRIL AGGREGATES

NºPublicación:  WO2025046049A1 06/03/2025
Solicitante: 
UNIV UTRECHT HOLDING B V [NL]
UNIVERSITEIT UTRECHT HOLDING B.V

Resumen de: WO2025046049A1

The present invention relates to molecules that are capable of binding to amyloid fibril aggregates. The invention further describes methods for detecting the presence of amyloid fibril aggregates in a sample or a subject. The invention even further describes methods for treating pathologies caused by amyloid fibril aggregates.

DIGESTED DDIT4L PRODUCT AS DIAGNOSTIC MARKER FOR ALZHEIMER'S DISEASE

NºPublicación:  EP4516923A1 05/03/2025
Solicitante: 
PLASMARKER BIOTECHNOLOGY CO LTD [CN]
Plasmarker Biotechnology Co., Ltd
EP_4516923_A1

Resumen de: EP4516923A1

The present application relates to a digested DDIT4L product as a diagnostic marker for Alzheimer's disease, and use thereof in diagnosing Alzheimer's disease. In particular, the present application relates to use of a substance for detecting a digested intron retention (DIR) product encoding DNA-damage-inducible transcript 4 like (DDIT4L) in a sample of a subject in preparing a product for diagnosing Alzheimer's disease or a mild cognitive disorder and/or assessing (e.g., grading or staging) cognitive disorder progression, a related product thereof, and a method for screening a medicament using the DIR product.

神経変性疾患を検出する方法

NºPublicación:  JP2025029000A 05/03/2025
Solicitante: 
ナショナルユニヴァーシティーオブシンガポール
JP_2025029000_PA

Resumen de: US2022397580A1

The present disclosure relates generally to the field of neurology. In particular, the disclosure relates to a method of detecting a neurodegenerative disease in a subject and methods of treatment thereof. The methods include detecting the level of an exosome-bound aggregated biomarker in a sample obtained from the subject, wherein an increased level of the exosome-bound aggregated biomarker as compared to a reference indicates that the subject is suffering from a neurodegenerative disease. Also described are methods for detecting a subject at risk of developing amyloidosis or a neurodegenerative disease, methods for detecting and treating amyloidosis or a neurodegenerative disease in a subject, and methods of determining the aggregation state of a biomarker in a sample.

Anti-tau mtbr antibodies and methods to detect cleaved fragments of tau and uses thereof

NºPublicación:  IL318722A 01/03/2025
Solicitante: 
WASHINGTON UNIV [US]
WASHINGTON UNIVERSITY
IL_318722_A

Resumen de: AU2023329330A1

Provided herein are antibodies, or fragments thereof, that specifically bind to a microtubule-binding region (MTBR) of tau, and uses thereof. Further provided are methods of detecting species of MTBR in blood or cerebral spinal fluid, and the use of such detection for diagnosing, prognosing, or staging pathological features and/or clinical symptoms of tauopathies, and to choose treatments appropriate for a given disease stage.

SEROLOGICAL ASSAYS FOR PARKINSON'S DISEASE

NºPublicación:  US2025067731A1 27/02/2025
Solicitante: 
NEURODEX INC [US]
NeuroDex, Inc
JP_2025500293_A

Resumen de: US2025067731A1

The present invention provides improved and minimally invasive biomarker-based diagnostics for synucleinopathies (e.g., Parkinson's disease (PD)). The invention further provides assays and methods for analysis of biological samples, for the evaluation and determination of characteristics pertaining to pathological processes associated with α-synuclein, and to methods for determining the suitability of analytical agents for diagnosis of synucleinopathies. More specifically, the invention in embodiments thereof provides improved methods comprising specific detection and quantification of α-synuclein-based biomarkers from low volumes of biological samples.

METHODS FOR PREDICTING COGNITIVE DECLINE IN A SUBJECT

NºPublicación:  WO2025040574A1 27/02/2025
Solicitante: 
INSTITUT NATIONAL DE LA SANTE ET DE LA RECH MEDICALE [FR]
ETABLISSEMENT FRANCAIS DU SANG EFS [FR]
UNIV TOULOUSE III - PAUL SABATIER [FR]
CENTRE NATIONAL DE LA RECHERCHE SCIENT [FR]
CENTRE HOSPITALIER UNIV DE TOULOUSE [FR]
INSTITUT NATIONAL DE RECH POUR LAGRICULTURE LALIMENTATION ET LENVIRONNEMENT INRAE [FR]
INSTITUT NATIONAL DE LA SANT\u00C9 ET DE LA RECHERCHE M\u00C9DICALE,
ETABLISSEMENT FRAN\u00C7AIS DU SANG (EFS),
UNIVERSIT\u00C9 TOULOUSE III - PAUL SABATIER,
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE,
CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE,
INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (INRAE)
WO_2025040574_A1

Resumen de: WO2025040574A1

Alzheimer's disease is strongly linked to biological aging and bioenergetic abnormalities. Systemic dysregulation of metabolism is a hallmark of the physiological decline of tissues with age. We aimed to explore untargeted metabolomic profiling of blood samples from amyloid-positive people to distinguish individuals who progressed to cognitive decline from those who remained cognitively intact despite having amyloid deposits in the brain. A minimal signature of 9 metabolites identified decliners and non-decliners of cognitive function in participants with an amyloid load. These findings are of clinical importance as they suggest that a metabolic fingerprint may help to predict patients who will develop cognitive decline. Due to the high prevalence of brain amyloid-positivity in older adults, identifying adults who will have cognitive decline will enable the development of personalized and early interventions. The present invention relates to an in vitro method for predicting cognitive decline in a subject comprising the step of determining the level of at least one metabolite selected in the group consisting of 3-hydroxybutyrate, acetone, triglyceride 48:3, glucose, citrate, succinate, methionine, serine, sphingomyelin d18:1/C26:0 in a biological sample obtained from the subject.

REGIONAL TAU IMAGING FOR DIAGNOSING AND TREATING ALZHEIMER'S DISEASE

NºPublicación:  US2025064417A1 27/02/2025
Solicitante: 
ELI LILLY AND COMPANY [US]
Eli Lilly and Company
KR_20240145486_PA

Resumen de: US2025064417A1

Disclosed are methods for using regional tau PET scans for identifying a subject having or suspected of having, diagnosing, and treating Alzheimer's disease. The methods are particularly useful for treating and diagnosing a patient as susceptible and at risk for developing amyloid-beta and cognitive dysfunction using tau-PET imaging based on regional tau PET measures.

USE OF IL-27 PROTEIN IN PREPARATION OF PRODUCT FOR TREATING AND/OR DELAYING ALZHEIMER'S DISEASE

NºPublicación:  EP4512413A1 26/02/2025
Solicitante: 
GUANGDONG JIANTEBO BIOTECHNOLOGY CO LTD [CN]
Guangdong Jiantebo Biotechnology Co., Ltd
EP_4512413_PA

Resumen de: EP4512413A1

Use of an interleukin 27 (IL-27) protein in preparation of a product for treating and/or delaying Alzheimer's disease (AD) is provided, belonging to the technical field of biomedicine. The IL-27 protein refers to a recombinant IL-27 protein targeting a therapeutic target II,-27, and is selected from the group consisting of a mouse-derived IL-27 protein and a human-derived IL-27 protein, as well as a mammalian IL-27 protein other than the mouse-derived IL-27 protein and the human-derived IL-27 protein. The recombinant IL-27 protein can effectively alleviate the AD caused by Aβ deposition, and can selectively bind to a target receptor, thereby ensuring an accuracy of test results. The protein receptor is highly expressed in the dentate gyrus region of hippocampus, and guarantees drug targeting to the greatest extent. The recombinant IL-27 protein also shows desirable application prospects, can quickly and effectively improve and alleviate behaviors such as the memory impairment in mice with AD, and has a clinical transformation value.

RANタンパク質関連神経学的疾患を処置するための方法

NºPublicación:  JP2025026843A 26/02/2025
Solicitante: 
ユニバーシティーオブフロリダリサーチファンデーション,インク.
JP_2025026843_PA

Resumen de: US2022267776A1

Aspects of the disclosure relate to compositions and methods for the diagnosis and/or treatment of certain neurodegenerative diseases, for example those diseases associated with repeat-associated non-ATG (RAN) translation proteins, such as Alzheimer's disease (AD). In some embodiments, the disclosure relates to identifying a subject having a RAN protein-associated disease by detecting expression or activity of repeat-associated non-ATG (RAN) translation proteins (e.g., RAN proteins). In some embodiments, the disclosure relates to methods of treating a RAN protein-associated disease by administering to a subject in need thereof an agent that reduces expression or activity of RAN proteins.

抗A-βタンパク質抗体、その方法及び使用

NºPublicación:  JP2025026427A 21/02/2025
Solicitante: 
エフ.ホフマン-ラロシュアーゲー
JP_2025026427_A

Resumen de: US2025051429A1

Herein is reported an antibody that binds to human A-beta protein, wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain comprising CDRs selected from (1) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 83; or (3) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.

PLASMA ASSAY FOR DETECTING CNS-DERIVED TAU PEPTIDES

NºPublicación:  WO2025037271A1 20/02/2025
Solicitante: 
JANSSEN PHARMACEUTICA NV [BE]
JANSSEN PHARMACEUTICA NV
WO_2025037271_A1

Resumen de: WO2025037271A1

Provided herein are methods and assays for detecting central nervous system (CNS)-derived tau peptides in blood-based samples from subjects, involving the use of a capture antibody that binds to a tau epitope, and a detection antibody that binds to an epitope comprising amino acids residues that span the junction of Exon 4 and Exon 5 of CNS-derived tau.

DIGESTED DDIT4L PRODUCT AS DIAGNOSTIC MARKER FOR ALZHEIMER'S DISEASE

NºPublicación:  US2025060376A1 20/02/2025
Solicitante: 
PLASMARKER BIOTECHNOLOGY CO LTD [CN]
PLASMARKER BIOTECHNOLOGY CO., LTD
WO_2023208119_A1

Resumen de: US2025060376A1

The present application relates to a digested DDIT4L product as a diagnostic marker for Alzheimer's disease, and use thereof in diagnosing Alzheimer's disease. In particular, the present application relates to use of a substance for detecting a digested intron retention (DIR) product encoding DNA-damage-inducible transcript 4 like (DDIT4L) in a sample of a subject in preparing a product for diagnosing Alzheimer's disease or a mild cognitive disorder and/or assessing (e.g., grading or staging) cognitive disorder progression, a related product thereof, and a method for screening a medicament using the DIR product.

p53 PEPTIDES AS MARKERS IN THE DIAGNOSIS AND PROGNOSIS OF ALZHEIMER'S DISEASE

NºPublicación:  US2025060377A1 20/02/2025
Solicitante: 
DIADEM SPA [IT]
Diadem SpA

Resumen de: US2025060377A1

Disclosed are p53 peptides and their use as biomarkers in the diagnosis and/or prognosis of Alzheimer's disease (AD) in a biological sample. The invention also provides for a diagnostic method based on a highly accurate mass spectrometry analysis for the diagnosis of Alzheimer's disease at the pre-clinical and prodromal stages of the disease and for the prognosis of cognitive decline in a subject, by quantitating the levels of said p53 peptides specifically in human plasma of patients.

METHODS FOR DIAGNOSING AND/OR TREATING ALZHEIMER'S DISEASE

NºPublicación:  US2025059584A1 20/02/2025
Solicitante: 
SEQ BIOMARQUE LLC [US]
SEQ BIOMARQUE, LLC

Resumen de: US2025059584A1

Provided are methods for diagnosing and/or treating Alzheimer's disease. Also provided are biomarkers, and combinations of biomarkers, that are diagnostic for the presence and progression of Alzheimer's disease, and treatment thereof.

COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND/OR TREATMENT OF AMYLOID B PEPTIDE PROTEINOPENIA IN ALZHEIMER'S AND OTHER DISEASES

NºPublicación:  WO2025038979A1 20/02/2025
Solicitante: 
LVIS REGAIN LP [US]
LVIS-REGAIN LP
WO_2025038979_A1

Resumen de: WO2025038979A1

Material compositions and/or methods useful for the prophylaxis and/or treatment of protein depletion (proteinopenia) are provided, including material compositions that retains native function of a peptide/protein while limiting and/or preventing amyloid formation and/or aggregation of said peptide/protein. Material compositions and formulations for enhancing peptide/protein solubility, stability, circulation time, receptor interaction, brain penetrance, CSF half-life, facilitating peptide/protein synthesis and purification are also provided.

CELL THERAPY FOR ALZHEIMER'S DISEASE

NºPublicación:  EP4508073A1 19/02/2025
Solicitante: 
UNIV NEBRASKA [US]
Board of Regents of the University of Nebraska
WO_2023201133_A1

Resumen de: WO2023201133A1

Provided are engineered cells that include a T cell receptor (TCR) or antigen-binding fragment thereof that binds to amyloid beta, and methods of engineering and using such cells, such as in methods of treatment, diagnosis, and monitoring of therapeutic effectiveness, of diseases or conditions, such as those associated with amyloid beta, e.g., Alzheimer's Disease.

A BIOMARKER FOR DETERMINING ALZHEIMER'S DISEASE

NºPublicación:  EP4508433A1 19/02/2025
Solicitante: 
UNIV OF EASTERN FINLAND [FI]
University of Eastern Finland
WO_2023198960_A1

Resumen de: WO2023198960A1

The present disclosure relates to a method for determining a risk of development or risk of presence of Alzheimer's disease in a human subject comprising analyzing an activity of a PIEZO1 receptor. The disclosure also relates to a kit for determining a risk of development or risk of presence of Alzheimer's disease according to the present method. The disclosure also relates to an in vitro use of a PIEZO1 receptor as a biomarker and and determination of intracellular calcium level as a biomarker for determining a risk of development or risk of presence of Alzheimer's disease in a human subject.

PEPTIDE BIOMARKER FOR NEUROLOGICAL DISEASE, IN PARTICULAR MOTOR NEURON DISEASE

Nº publicación: WO2025032091A1 13/02/2025

Solicitante:

F HOFFMANN LA ROCHE AG [CH]
HOFFMANN LA ROCHE INC [US]
F. HOFFMANN-LA ROCHE AG,
HOFFMANN-LA ROCHE INC

WO_2025032091_A1

Resumen de: WO2025032091A1

The present invention relates to a splice variant of a CERT1 protein that acts as a biomarker for a TDP-43 pathology, in particular motor neuron diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD), but also other neurological diseases, such as Alzheimer's disease. In particular, the present invention relates to methods for identifying a splice variant of CERT1 comprising a cryptic peptide sequence, and to related methods of identifying a TDP-43 pathology and/or reduced TDP-43 function in a subject and to methods for predicting whether a therapy is likely to be successful. Also claimed are antibodies binding to the CERT1 splice variant and kits comprising the antibody.

traducir